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 We retrospectively reviewed the history, records of detailed 
examination and/or treatment, and cytologic/histologic 
specimens of 32 adenocarcinoma cases (0.006%) detected 
among 482,451 examinees in a mass screening for cervical 
cancer conducted over a 20-year period (1975-1994). 
 The detection rate of adenocarcinoma had increased 
gradually until 1989 with the increase of total examinees but 
became markedly lower in the last five-year period (p = 
0.0227), probably because of the significant decrease in the 
number of initial examinees (p<0.0001). The frequency of 
early-stage adenocarcinoma (stage 0 or Ia) was 37.5% (12/ 
32), markedly higher than the 8.4% (7/83) of the adenocar-
cinoma cases treated at our institution during the same 
period (p = 0.0004). Glandular epithelial neoplasms were 
suggested by cervical smears at detection in only 5/12 
(41.7%) of the early-stage adenocarcinoma cases and in 17/ 
20 (85.0%) of the frankly invasive adenocarcinoma cases 
(p= 0.0184). Atypical glandular epithelial cells could not be 
found in the smears at detection from the remaining 10 cases. 
Atypical cells from coexisting squamous cell neoplasms 
were found. The rate of the histologic coexistence of 
squamous cell neoplasms was 9/12 (75.0%) in the early-
stage group and 6/20 (30.0%) in the frankly invasive group 
(p = 0.0269). This rate tended to decrease with the progress 
of the stage. 
  Mass screening can detect early-stage adenocarcinoma in 
cervical smears, but half or more of the cases are discovered 
in smears with atypical cells from coexisting squamous cell 
neoplasms and incidentally found later in histologic speci-
mens. To improve the accuracy of detecting cervical 
adenocarcinomas, we should investigate the cytologic 
features of atypical glandular epithelial cells obtained from 
early-stage adenocarcinomas. The its epidemiologic profile 
of this cancer should be furthur delineated for efficient mass 
screening programs.
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Introduction 
 A mass screening for uterine cancer has been performed
in Japan since 1983 by local governments under the Health 
and Medical Services Law in women 30 or more years old. 
The number of examinees is slowly but steadily increasing. 
Most of the uterine cervical cancer patients detected by 
this mass screening have a squamous cell carcinoma. In the 
1980s, an absolute increase of the incidence of adeno-
carcinoma in uterine cervical cancer was reported in 
Europe and the United States"), and in Japan, a two- to 
three-fold increase of the incidence was reported in certain 
areas or at certain institutions,"). In a mass screening for 
uterine cancer, however, the assessment of adenocarci-
noma by cytologic diagnosis is more difficult than that of 
squamous cell carcinoma. Thus, adenocarcinoma may 
often be overlooked, and this may decrease the overall 
accuracy of cytologic diagnosis in mass screening" 
 Therefore, in the present study, the authors investigated 
the detection of adenocarcinoma of the uterine cervix in 
the mass screening for uterine cancer in Nagasaki 
Prefecture and then retrospectively reviewed the main 
cytodiagnostic and clinicopathological factors which 
would be involved in the improvement of the accuracy of 
cytologic diagnosis in mass screening.
Subjects and Methods 
Subjects 
 For the 20-year period from April 1975 to March 1994, 
the mass screening conducted once a year using mass 
screening cars under the direction of the Nagasaki 
Prefecture Medical Center had 482,451 examinees 
(initial+repeated) 30 or more years old who resided in the 
nine health care regions (79 cities/towns/villages) of 
Nagasaki Prefecture. We retrospectively reviewed the all 
of the examinees' records. The records of all of the cases 
who were assessed as suspicious or positive by the screen-
ing smears in the mass screening and presented to the 
institutions for detailed examination or treatment were 
reviewed to investigate the smear results and histologic 
results at these institutions after the mass screening and
to identify the adenocarcinomas of the uterine cervix 
(including the mixed type of adenocarcinoma and 
squamous cell carcinoma) detected by the mass screening. 
  Pure adenocarcinoma and the mixed type of adeno-
carcinoma and squamous carcinoma were both regarded as 
"adenocarcinoma" in the present study for the following 
reasons. 1) In the mixed type of adenocarcinoma and 
squamous cell carcinoma, cells thought to be transitional 
from adenocarcinoma and squamous cell carcinoma are 
found, and the components of these two types of carci-
noma may originate in the same stem cells (reserve 
cells)"); during the subsequent progress of the carcinoma, 
the adenocarcinoma may obliterate the squamous cell 
carcinoma and present the morphology of pure adeno-
carcinoma. 2) The efficiency of a mass screening for 
uterine cervical cancer is recognized for squamous cell 
carcinoma of the cervix, but not for adenocarcinoma or 
the mixed type of adenocarcinoma and squamous cell 
carcinoma",") 
 The mass screening history (initial and repeated screen-
ings) and clinicopathological factors in the adenocarci-
noma cases detected by the mass screening were 
investigated with reference to the records at the institu-
tions which conducted the detailed examination and/or 
treatment, and compared with those in the squamous cell 
carcinoma cases detected by the same mass screening at 
the same period or the uterine cervical cancer cases treated 
at our institution during the same period. The specimens 
of cytologic and histologic diagnosis from all of the 
adenocarcinoma cases were collected and reviewed at our 
laboratory. 
The mass screening program for uterine cervical cancer 
 Ectocervical and endocervical scraping smears were 
collected using a spatula and swab, respectively, from all 
of the examinees of the mass screening after the investiga-
tion of their anamneses. These smears were immediately 
fixed in 95% alcohol fixative, transferred to the Nagasaki 
Prefecture Medical Health Center and stained for the 
Papanicolaou test. 
 All of the smears were screened by 1 to 3 cytotech-
nologists and those which were assessed to be suspicious or 
positive were further rescreened by 2 to 4 other cytotech-
nologists. Then, these abnormal smears were sent to our 
institution and 1 to 2 specialists in cytopathology reviewed 
them for the presence of histologic lesions. The examinees 
with abnormal smears were contacted by the institutions 
in their health care region for detailed examination. 
Criteria of clinical staging, cytologic diagnosis and 
histologic diagnosis 
 Squamous cells in the cervical scraping smears were 
assessed by "Nichibo" cytologic classification and
columnar epithelial cells by Papanicolaou classification. 
Based on these two classifications, the smears were divided 
into three groups : negative (class I and class II), suspi-
cious (class III), and positive (class IV and class V). 
 The clinical stage and histologic type of the uterine 
cervical cancers were classified following the criteria 
specified in the "General Rules for Clinical and 
Pathological Management of Uterine Cervical Cancer" 16) 
Statistical analysis 
 Comparisons between groups were made by the Fisher 
exact method, and p<0.05 was defined as significantly 
different.
Results 
Incidence of cervical carcinoma detected in the mass 
screening 
 The results of the mass screening for uterine cancer over 
the 20-year period from April 1975 to March 1994, divided 
into five-year periods, are shown in Table 1. The number of 
the mass screening examinees steadily increased, from 
86,578 in the first five-year period to 150,856 in the last 
five-year period. The largest increase was for the five-year 
period from 1985 to 1989, during which the mass screening 
system introduced in 1983 in accordance with the Health 
and Medical Law had been spreading and stabilized. The 
number of examinees during this period was about 31,000 
more than at during the preceding five-year period, and the 
number of examinees who needed detailed examination was 
significantly higher than those during the other five-year 
periods (p<0.0001). 
 The detection rate of squamous cell carcinoma of the 
uterine cervix in the mass screening for uterine cancer 
tended to decrease slightly every five-year periods. The 
detection rate for the whole twenty-year period was 
0.10%. The detection rate for adenocarcinoma and the 
mixed type of adenocarcinoma and squamous cell carci-
noma of the uterine cervix for the whole twenty-year 
period was low, 0.0066%. However, it gradually increased 
until 1989 in every five-year period, reaching 0.0109% for 
the five-year period from 1985 to 1989. It significantly 
decreased (to 0.0033%) in the last five-year period com-
pared with the preceding five-year period (p = 0.0227) 
(Table 1). 
Clinical stage distribution of uterine cervical carcinomas 
 The clinical stage distribution of cervical carcinomas 
detected in the mass screening and that of the cases treated 
in our institution are shown in Tables 2 and 3, respectively. 
In total, 32 cases of adenocarcinoma of the cervix
Table 1. Numbers of examinees and cervical carcinomas detected in the mass screening for uterine cancer in Nagasaki 
Prefecture, Japan.
  Time period Total No. of No. of examinees No. of cases of No. of cases of No. of cases of No. of cases of 
                 examinees needing detailed SCC detected AC detected MAS detected AC & MAS 
                                    examinations detected
    1975-79 86,578 407 (0.47) 131 (0.15) 4 (0.0046) 0 4 (0.0046) 
    1980-84 106,857 507 (0.47) 121 (0.11) 4 (0.0037) 4 (0.0037) 8 (0.0075) 
    1985-89 138,160 1,040 (0.75) 134 (0.10) 11 (0.0080) 4 (0.0029) 15 (0.0109) 
    1990-94 150,856 651 (0.43) 90 (0.06) 4 (0.0027) 1 (0.0007) 5 (0.0033) 
    Total 482,451 2,605 (0.54) 476 (0.10) 23 (0.0048) 9 (0.0019) 32 (0.0066) 
Numbers in parentheses indicate the ratio to total examinees (%). 
SCC, squamous cell carcinoma ; AC, adenocarcinoma ; MAS, mixed type of adenocarcinoma and squamous cell carcinoma.
Table 2. Clinical stage distribution of cervical carcinomas detected in the mass screening, by histologic type.
     Clinical stage No. of cases No. of cases No. of cases No. of cases                         of SCC of AC of MAS of AC & MAS
     Stage 0 307 (64.5%) 3 (13.0%) 4 (44.4%) 7 (21.9%) 
     Stage Ia 100 (21.0%) 3 (13.0%) 2 (22.2%) 5 (15.6%) 
     Stage lb 52 (10.9%) 13 (56.5%) 3 (33.3%) 16 (50.0%) 
     Stage II-III 17 ( 3.6%) 4 (17.4%) 0 4 (12.5%) 
      Total 476 (100%) 23 (100%) 9 (100%) 32 (100%) 
SCC, squamous cell carcinoma ; AC, adenocarcinoma ; MAS, mixed type of adenocarcinoma and squamous cell carcinoma.
Table 3. Clinical stage distribution of cervical carcinomas 
treated at the Nagasaki University School of Medicine 
(1975-1994), by histologic type.
   Clinical stage No. of cases No. of cases                   of SCC of AC & MAS
  Stage 0 346 (35.3%) 3 ( 3.6%) 
  Stage la 137 (14.0%) 4 ( 4.8%) 
  Stage Ib 209 (21.3%) 49 (59.0%) 
  Stage IIa-b 212 (21.6%) 21 (25.3%) 
  Stage IIIa-b 57 ( 5.8%) 5 ( 6.0%) 
  Stage IVa-b 19 ( 1.9%) 1 ( 1.2%) 
    Total 980 (100%) 83 (100%) 
SCC, squamous cell carcinoma; AC, adenocarcinoma; MAS, 
mixed type of adenocarcinoma and squamous cell carci-
noma.
Table 4. Clinical stage distribution of cervical adenocarci-
nomas* detected at initial and repeated mass screenings.
                No. of cases No. of cases 
Clinical stage detected at detected at Total                 initial repeated 
                screening screening
  Stage 0 2 5 7 
  Stage Ia 1 4 5 
  Stage lb 9 7 16 
  Stage IIb 3 1 4 
   Total 15 17 32
* Including the mixed type of adenocarcinoma and squa-
mous cell carcinoma.
(including the mixed type of adenocarcinoma and 
squamous cell carcinoma) were detected. The number of 
cases with adenocarcinoma at an early stage (stage 0 or 
stage Ia) was 12 (37.5%), significantly lower than the 
detection rate of squamous cell carcinoma at the early 
stage (407/476 cases, 85.5%) (p<0.0001) (Table 2). 
However, it was markedly higher than the detection rate 
of adenocarcinoma of the cervix at the early stage treated 
at our institution in the 20-year period from 1975 to 1994 
(7/83 cases, 8.4%) (p = 0.0004) (Table 3). 
 The clinical stage distribution of the 32 adenocarcinoma 
cases detected by the intial and repeated mass screenings 
is shown in Table 4. The cases with adenocarcinoma of the 
cervix detected at an initial mass screening and at a 
repeated mass screening were 15 (46.9%) and 17 (53.1%), 
respectively, without a large difference between two
groups. The rates of adenocarcinoma at an early stage 
(stage 0 or stage Ia) and frankly invasive adenocarcinoma 
(stage Ib or stage IIb) were 3/15 cases (20.0%) and 12/15 
cases (80.0%) in the initial screening group, and 9/17 cases 
(52.9%) and 8/17 cases (47.1%) in the repeated screening 
group, respectively (Table 4). The adenocarcinomas in the 
early stage tended to be detected in the repeated screening, 
and the frankly invasive adenocarcinomas tended to be 
detected in the initial screening, but there was no signifi-
cant difference between these two groups in their detection 
distribution (p = 0.0759). 
Smear results at detection of cervical adenocarcinomas by 
clinical stage 
 The results of the review of the smears at the detection
Table 5. Smear results at detection of cervical adenocarci-
nomas* detected in the mass screening, by clinical stage.
                   No. of cases No. of cases  Clinical stage 
presumed SN presumed GD Total                                 or AC 
  Stage 0 4 3 7 
  Stage la 3 2 5 
  Stage Ib 3 13 16 
  Stage IIb 0 4 4 
    Total 10 22 32
* Including the mixed type of adenocarcinoma and squa-
mous cell carcinoma. 
SN, squamous cell neoplasms (including dysplasia, carci-
noma in situ, and microinvasive and invasive carcinoma) ; 
GD, glandular dysplasia ; AC, adenocarcinoma.
Table 6. Number of cases with coexistence of squamous cell 
neoplasms in cervical adenocarcinomas* detected in the mass 
screening, by clinical stage.
               No. of cases with coexistence of 
 Clinical Total 
  stage none dysplasia carcinoma invasi
ve 
                          in situ carcinoma 
Stage 0 1 2 4 0 7 
Stage I 2 1 2 0 5 
Stage Ib 10 3 1 2 16 
Stage IIb 4 0 0 0 4 
 Total 17 6 7 2 32 
* Including the mixed type of adenocarcinoma and squa-
mous cell carcinoma.
of adenocarcinomas of the cervix (including the mixed 
type of adenocarcinoma and squamous cell carcinoma) are 
shown in Table 5. 
 It was possible to diagnose glandular epithelial neo-
plasms such as glandular dysplasia and adenocarcinoma 
from the smears at detection in 22/32 adenocarcinoma 
cases (68.8%). They could be diagnosed in only 5/12 of the 
cases (41.7%) of early-stage adenocarcinoma. Of the 
frankly invasive adenocarcinomas (stage Ib + stage IIb), it 
was possible to diagnose the neoplasms in 17/20 cases 
(85.0%) ; this rate was significantly higher than that of 
the early-stage adenocarcinoma (p = 0.0184). The diagnos-
able rate was 3/7 cases (42.9%) at stage 0 and 2/5 cases 
(40.0%) at stage Ia of the early-stage adenocarcinomas, 
with no significant difference. This rate was 13/16 cases 
(81.3%) at stage Ib and 4/4 cases (100%) at stage IIb and 
tended to increase with the progress of the adenocarcinoma 
(Table 5). 
 The remaining 10 cases (31.3%) were comprised of 7 
cases (58.3%) of early-stage adenocarcinoma and 3 cases 
(15.0%) of frankly invasive adenocarcinoma ; their 
smears at detection revealed only atypical cells originat-
ing in the coexisting squamous cell neoplasms. Thus, the 
adenocarcinoma of the cervix in these cases was detected 
incidentally by biopsy and/or conization specimens or 
hysterectomy specimens. 
Frequency of coexisting squamous cell neoplasms in 
detected adenocarcinoma cases by clinical stage 
 As shown in Table 6, early-stage adenocarcinomas and 
frankly invasive adenocarcinomas histologically coexisted 
with squamous cell neoplasms in 9/12 cases (75.0%) and 
6/20 cases (30.0%), respectively, indicating a high fre-
quency of coexistence for early-stage adenocarcinomas 
(p = 0.0269). The frequencies of coexistence were 6/7 cases 
(85.7%) at stage 0, 3/5 cases at stage la (60.0%), 6/16 
cases (37.5%) at stage Ib and 0/4 cases (0%) at stage IIb,
showing a tendency to decrease with the progress of stage 
(Table 6). Of the 9 cases of early-stage adenocarcinoma 
coexisting with squamous cell neoplasms, more than half 
(6 cases) coexisted with squamous cell carcinoma in situ. 
Clinical features of adenocarcinomas detected in the mass 
screening 
 The median age was 46 (33-62) years old in the 7 stage 0 
cases, 36 (33-65) in the 5 stage Ia cases, 57.5 (32-72) in the 
16 stage Ib cases and 49.5 (39-67) in the 4 stage IIb cases. It 
was 51 (32-72) in the total 32 cases. When divided into two 
groups of adenocarcinoma at an early stage (stage 
0+stage Ia) and frankly invasive adenocarcinoma (stage 
Ib+stage IIb), the median ages were 35.5 (33-65) and 57.5 
(32-72) years old, respectively. The postmenopausal 
women in these two groups were 4/12 cases (33.3%) and 
12/20 cases (60.0%), respectively. 
 The median numbers of gravidity and parity were 3 (0-7) 
and 2.5 (0-5) in the early-stage adenocarcinoma group and 
4 (1-10) and 3 (1-9) in the frankly invasive adenocarci-
noma group. In total, the frequencies of nulligravidity and 
nulliparity were both 1/32 cases (3.1%). 
 Atypical genital bleeding occurred in 3/12 cases (25.0%) 
in the early-stage adenocarcinoma group and 8/20 cases 
(40.0%) in the frankly invasive adenocarcinoma group; 
i.e., in 11/32 cases of adenocarcinoma (34.4%).
Discussion 
 The frequency of adenocarcinoma in carcinoma of the 
uterine cervix has been shown to be increasing not only 
relatively with the decrease of squamous cell carcinoma 
but also absolutely2'1,5'. Some registries recorded a 2 % or 
more annual increase of the frequency in the 1972-1982 
period, with the most marked increase in young women in 
middle to upper income levels who are likely to use oral
contraceptives',,'). Parazzini et al'). also reported a doubled 
frequency in the age group of less than 35 years old during 
a recent 10-year period. In Japan, Kimura et al'). and 
Hasumi et al"). reported approximately tripled and dou-
bled frequencies in certain regions and institutions, 
respectively.In the present study, the detection rate for 
cervical carcinoma (squamous cell carcinoma, adenocarci-
noma, and the mixed type of adenocarcinoma and 
squamous cell carcinoma) in the last five-year period of 
the mass screening for uterine cancer was 95/150,856 
(0.063%), significantly lower than the 149/138,160 
(0.108%) in the preceding five-year period (p<0.0001, 
chi-square test). The detection rate in each year of the last 
five-year period was reviewed; these rates were 24/30,139 
(0.080%) in 1990, 12/31,497 (0.038%) in 1991, 13/28,437 
(0.046%) in 1992, 30/31,122 (0.096%) in 1993 and 16/ 
29,661 (0.054%) in 1994. We did not find a gradually 
decreasing tendency year after year, but the detection rate 
in each single year was lower than that during the preced-
ing five-year period, 0.108%. However, the detection rates 
in each year during the last five-year period (1989-1993) in 
the nationwide statistics obtained by mass screenings for 
uterine cancer were 2,881/3,710,182 (0.078%), 2,722/ 
3,843,501 (0.071%), 3,045/4,182,270 (0.073%), 2,749/ 
3,992,439 (0.069%) and 2,680/4,133,959 (0.065%)17). The 
national detection rate tended to decrease gradually year 
after year. 
 The number and frequency of adenocarcinomas (includ-
ing the mixed type of adenocarcinoma and squamous cell 
carcinoma) of the uterine cervix detected in the mass 
screening in this study tended to increase until 1989, but 
the increasing tendency was not found at all in the subse-
quent five-year period. However, this may be partly 
attributed to the slowing of the spread of the mass 
screening programs for uterine cancer, and to the increase 
of the rate of repeated examinees. In the mass screening 
for cancer, if the rate of initial examinees among total 
examinees is higher, the detection rate of cancer usually 
becomes higher. The rates of initial examinees among the 
total examinees in each of the three 5-year periods in the 
present study (1980-1984, 1985-1989 and 1990-1994) were 
20,996/106,857 (19.6%), 19,010/138,160 (13.8%) and 
12,718/150,856 (8.4%), respectively. The rate in the last 
five-year period proved to be significantly lower than that 
of the others(p<0.001, chi-square test). This may explain 
the low detection rate of adenocarcinoma of the cervix 
during this period. The same phenomenon was noted in the 
detection rate of squamous cell carcinoma of the cervix. 
The results of the mass screening program in the present 
study thus do not preclude an increasing tendency of 
adenocarcinoma of the cervix. 
 The greatest significance of the mass screening for 
cancer lies in the contribution of the screening results 
toward the decrease of both the cancer incidence and 
mortality rate in the target region or population. Mass
screening has been demonstrated to be effective in detect-
ing squamous cell carcinoma of the cervix, but its efficacy 
in the detection of adenocarcinomas is not estab-
lished"','"). We should consider this as a problem to be 
solved in present and future mass screening programs for 
cervical cancer. The present detected number (32 cases) and 
rate (0.0066%) for adenocarcinoma and the mixed type of 
adenocarcinoma and squamous cell carcinoma of the cervix 
in the mass screening program for cervical cancer for the 
past 20 years in Nagasaki Prefecture were markedly lower 
than the number (476 cases) and rate (0.01%) for squa-
mous cell carcinoma of the cervix in the same population. 
However, these 32 adenocarcinoma cases correspond to 
6.3% of the total 508 cases of cervical carcinoma detected 
in the mass screening, and this figure is not significantly 
different from the 83/1,063 cases (7.8%) for carcinoma of 
the cervix treated at our institution during the same 
period (p = 0.3020). Considering the general belief that 
adenocarcinoma accounts for 8 to 26% of primary carcino-
mas of the cervix'), the detection rate of adenocarcinoma 
of the cervix is not particularly low, as Sugimori et al11> 
reported. Therefore, the detection accuracy for adenocarci-
noma of the cervix in the present mass screening is no 
lower than it appears to be. We do not know the detection 
rate of adenocarcinoma of the cervix in relation to the 
examinees' history of undergoing the mass screening ; 
some reports describe a rate similar to that for frankly 
invasive carcinoma of the cervix (about 50%) and others 
describe a much lower rate"). In the present study, 46.9 % of 
the adenocarcinoma cases detected in the mass screening 
were detected in the initial screening, and 80% of them had 
frankly invasive adenocarcinoma at clinical stage lb orlIb. 
 In the present study, the rate of carcinoma at an early 
stage (stage 0 or stage la) in the adenocarcinomas of the 
cervix detected in the mass screening was significantly 
lower than that of squamous cell carcinoma detected in the 
same mass screening. As one of its histopathological 
factors, the results of our previous study") indicate that 
the lesions of adenocarcinoma at the early stage are 
generally small and buried deeply in the endocervical 
gland, which may make the lesions difficult to detect in 
cervical scraping smears. Besides this factor, adenocarci-
noma at an early stage may progress into frankly invasive 
carcinoma more quickly than dose squamous cell carci-
noma at an early stage and, as a result, the latent period 
as carcinoma in the early stage may be short and the 
chance to be detected could be decreased. From the aspect 
of cytodiagnosis, information regarding the cytologic 
findings of early-stage adenocarcinomas is insufficient in 
comparison with that on early-stage squamous cell carci-
nomas, and this may result in false negative cases. As 
measures to overcome this problem, the need to improve 
cytodiagnostic skill at recognizing different glandular 
lesions of the cervix has been pointed out"), and the use of 
better endocervical sampling devices was reported to
enhance the detection of adenoarcinoma22). 
  The rate of early-stage adenocarcinomas among the 
adenocarcinomas detected in the present mass screening 
was significantly higher than that of adenocarcinomas of 
the cervix treated at our institution during the same 
period. This result indicates a possibility of early detection 
of not only squamous cell carcinoma of the cervix but also 
adenocarcinoma of the cervix through mass screening. The 
results of the review of the smears at detection in the 
present study indicate that the existence of glandular 
epithelial neoplasms could be diagnosed in a relatively 
small number of cases (41.7%) by atypical glandular 
epithelial cells appearing in the smears of adenocarcinoma 
cases in early stage. The majority of the cases (58.3%) 
were identified by atypical squamous cells in the screening 
smears from the coexisting squamous cell neoplasms 
described below, and were indicated to require detailed 
examinations, where as the adenocarcinomas at an early 
stage were often found later in biopsy and/or conization 
specimens or hysterectomy specimens. This appears to be a 
limit of the detection of pure adenocarcinoma at an early 
stage without squamous cell neoplasms in smears from 
mass screening. Among the cases of adenocarcinoma in 
situ of the cervix, the rate of the cases with abnormal 
cervical smears (smears with atypical glandular epithelial 
cells and/or atypical squamous cells) has been reported to 
be 50-70%2x-25), much lower than the frequency in squamous 
cell carcinoma in situ. This rate is estimated to be further 
lower when limited to the smears with only atypical 
glandular epithelial cells. Retrospective studies of the 
cases diagnosed as having adenocarcinoma in situ of the 
cervix by conization have revealed that the rate of the 
cases suspected to have adenocarcinoma in situ by cervical 
smears, colposcopy or office cervical biopsy before 
conization was 16/26 cases (61.5%)25) or 20/40 cases 
(50.0%)26). Neither of these rates is high, indicating that 
many cases are found incidentally. 
 It is well known that early-stage adenocarcinomas often 
coexist histologically with squamous cell neoplasms of the 
cervix. The rate of coexistence is reported to be in a range 
of 50-90% in adenocarcinoma in situ (stage 0)13,25.31) and
31-67% in microinvasive adenocarcinoma (stage Ia) 31> 
These figures are high (85.7% and 60.0%) in the cases 
detected by the mass screening of the present study. The 
majority of coexisting squamous cell neoplasms are 
considered to be squamous cell carcinomas in situ, as 
found in the results of the present study. As mentioned in 
the above, these coexisting squamous cell neoplasms 
particularly help the identification of adenocarcinoma at 
an early stage. The rate of coexistence is relatively low in 
frankly invasive adenocarcinomala2Q -29.90) This rate was 
30.0% in the present study, and significantly lower than 
the 75.0% of the early-stage adenocarcinomas ; the reason 
for this is not known. We can consider as one of the 
possible reasons that, when adenocarcinoma in situ and
squamous cell carcinoma in situ coexist, the former is 
higher in biological malignancy and possibly obliterates 
the latter in the process of further development. 
 The median age (35.5 years old) of the patients with 
early-stage adenocarcinoma detected in the mass screening 
of the present study coincided well with the reports in 
Europe and the United States'-",",") and supports the 
findings that these patients are 10-20 years younger than 
those with frankly invasive adenocarcinoma31,1). However, 
most of the Japanese studies have reported the mean age 
of patients with adenocarcinoma in situ to be 44-45 years 
old",','). The reports in Europe and the United States 
indicate that the patients with adenocarcinoma of the 
cervix have a slight tendency toward nulligravidity, 
nulliparity and obesity'-') and share a few of the 
epidemiologic factors associated with endometrial carci-
noma of the uterine body'). The frequencies of nulligra-
vidity and nulliparity in the 32 cases of our study were 
both 3.1%. They were aiso low (2.7% and 10.8%) in our 
previous study of 37 cases of early-stage adenocarci-
noma13~. A possible difference in the etiology of adenocarci-
noma of the cervix between Europe/the United States and 
Japan should also be considered. The frequency of the 
patients with atypical genital bleeding is not definite, 
particularly in adenocarcinoma at an early stage, and has 
been reported to be in the range of 14-16%"1'-'). However, 
the majority of patients with early-stage adenocarcinoma 
are women at an reproductive age. Thus, we should con-
sider that atypical bleeding is not a feature specific to the 
lesions but that it is caused by coexisting cervical erosion. 
In order to improve the efficiency of mass screenings for 
adenocarcinoma of the cervix, the epidemiologic and 
clinical profiles of adenocarcinoma of the cervix should be 
further clarified, and a mass screening program should be 
designed based on these profiles.
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